Table 1 Summary of clinical data in each group of patients with COVID related vasculopathy

[I]

Age

–

41–50 years

7 (3%)

–

–

–

–

51–60 years

43 (16%)

–

4 (57%)

2 (67%)

–

61–70 years

192 (73%)

9 (90%)

3 (43%)

1 (33%)

–

71–80 years

14 (5%)

1 (10%)

–

–

–

81–90 years

6 (2%)

–

–

–

[II]

Sex

–

Male

188 (72%)

10 (100%)

3 (43%)

3 (100%)

–

Female

74 (28%)

–

4 (57%)

–

[III]

Chest symptoms

–

Present

247 (94%)

10 (100%)

6 (86%)

2 (67%)

–

Absent (initial presentation by vasculopathy)

15 (6%)

–

1 (14%)

1 (33%)

[IV]

Time of clinical presentation from onset of chest disease

–

1st week

102 (39%)

–

–

–

–

2nd week

111 (42%)

5 (50%)

3 (43%)

1 (33%)

–

3rd week

23 (9%)

3 (30%)

3 (43%)

1 (33%)

–

4th week

6 (2%)

2 (20%)

–

–

–

2nd month

3 (1%) (vasculitis)

–

–

–

–

3rd month

2 (1%) (vasculitis)

–

–

–

[V]

Main complaint

DLC

257 (98%)

Fever

7 (70%)

Abd. Pain

7 (100%)

Leg pain:

3 (100%)

Weakness/paresis

243 (93%)

Cough

10 (100%)

Vomiting

7 (100%)

Headache

5 (2%)

Dyspnea

10 (100%)

Hematemesis

4 (57%)

Dysarthria

4 (2%)

Chest pain

10 (100%)

Melena

4 (57%)

Vertigo

3 (1%)

Constipation

3 (43%)

Tinnitus

2 (1%)

Diarrhea

4 (57%)

Blurred vision

2 (1%)

[VI]

Comorbidities

–

Diabetes

24 (9%)

3 (30%)

2 (28%)

1 (33%)

–

Hypertension

120 (46%)

3 (30%)

3 (43%)

2 (67%)

–

Cardiomegaly (incidental)

78 (30%)

2 (20%)

4 (57%)

2 (67%)

–

Hepatic disease

18 (7%)

–

–

–

–

Renal disease

28 (11%)

–

–

–

–

Neoplastic

9 (3%)

–

–

–